NCT06112327View on ClinicalTrials.gov

Long-term Follow-up of Participants Dosed with an Investigational Gene Editing Therapy for Cardiovascular Disease

Enrolling by invitationOBSERVATIONAL
Enrollment

116

Participants

Timeline

Start Date

June 9, 2024

Primary Completion Date

October 31, 2039

Study Completion Date

October 31, 2039

Conditions
Atherosclerotic Cardiovascular DiseaseHeterozygous Familial HypercholesterolemiaHypercholesterolemia
Trial Locations (3)

Unknown

Clinical Study Center, Auckland

Clinical Study Center, Christchurch

Clinical Study Center, London

All Listed Sponsors
lead

Verve Therapeutics, Inc.

INDUSTRY